Abstract
ObjectiveTo study the occurrence of torsades de pointes (TdP) ventricular tachycardia in relation to use of drugs labelled with TdP risk, using two nationwide Swedish registers.DesignProspective register-based cohort study.SettingEntire Sweden.ParticipantsPersons aged ≥18 years prescribed and dispensed any drug classified with TdP risk during 2006–2017, according to CredibleMeds. Persons with a registered TdP diagnosis during the study period, using drugs labelled with known (TdP 1), possible (TdP 2) or conditional (TdP 3) risk at the incident of TdP were examined.Primary outcome measuresOccurrence of TdP in relation to exposure rates for individual drugs with TdP risk.Secondary outcome measuresConcurrent use of more than one TdP-labelled drug in a person with a TdP diagnosis.ResultsDuring the study period, 410 TdP cases using drugs with TdP risk labels at the incident were registered; 205 women and 205 men, mean age 74.0 and 71.5 years, respectively. Antidepressants dominated (129/410, 30%), followed by antiarrhythmics (17%). Diuretics and gastric acid-secretion inhibitors, with TdP risk related to induction of hypokalaemia or hypomagnesaemia, were used in 56% and 32% of the 410 TdP cases, respectively. Among the most used antidepressants, citalopram with known TdP 1 risk was associated with both a higher absolute number and incidence of TdP per 100 000 users (two to four times), compared with mirtazapine with possible (TdP 2), and sertraline with conditional (TdP 3) risk. Multiple risk factors, including advanced age, cardiovascular disease and treatment with more than one TdP-classified drug, were frequently observed.ConclusionsAntidepressants followed by antiarrhythmics dominated among TdP risk drugs used by adults with TdP diagnosis, the majority being ≥65 years. TdP risk class and concomitant medication should be considered when prescribing antidepressants to older patients.
Reference34 articles.
1. Drug-Induced Prolongation of the QT Interval
2. Cohagan B , Brandis D . Torsades de pointes (Internet). StatPearls Publishing, 2019. https://www.ncbi.nlm.nih.gov/books/NBK459388/
3. Credible Meds - Available TdP risk categories . Arizona center for education on research on therapeutics. Available: https://www.crediblemeds.org/ [Accessed 15 Oct 2019].
4. Drug-induced QT interval prolongation: mechanisms and clinical management
5. U.S. Food & Drug . FDA drug safety communication: revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses, 2012. Available: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献